MIMS Summary: NICE updates guidance for pregnant RhD negative women

NICE has reviewed its guidance on the routine use of antenatal anti-D prophylaxis in pregnant women.

There has been no change to the recommendations regarding which women are eligible for routine antenatal anti-D prophylaxis (RAADP) and the indications for its use.

Nice recommends RAADP as a treatment option for all pregnant women who are rhesus D (RhD) negative and who are not known to be sensitised to the RhD antigen.

The guideline appraised preparations that can be administered as single-dose or two-dose regimens and recommends that when a decision has been made to give RAADP, the treatment with the lowest cost should be used.

RAADP, usually administered by community midwives or at antenatal clinics, can be given as two doses of anti-D immunoglobulin of 500 IU (one at 28 weeks and one at 34 weeks gestation), as two doses of anti-D immunoglobulin of 1000-1650 IU (one at 28 weeks and one at 34 weeks gestation), or as a single dose of 1500 IU either at 28 weeks or between 28 and 30 weeks gestation.

Further information: NICE guidance on routine antenatal anti-D prophylaxis

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus